Targeted Radiotherapy for Prostate Cancer with an Oncolytic Adenovirus Coding for Human Sodium Iodide Symporter

Purpose: Oncolytic adenoviruses are promising tools for cancer therapy. Although several clinical reports have indicated both safety and promising antitumor capabilities for these viruses, there are only a few examples of complete tumor eradication. Thus, the antitumor efficacy of oncolytic adenoviruses needs to be improved. One potentially useful approach is combination with radiotherapy. Experimental Design: To target systemically administered radioiodide to tumors, we created Ad5/3-Δ24-human sodium iodide symporter (hNIS), a Rb-p16 pathway selective infectivity enhanced oncolytic adenovirus encoding hNIS. Results: Ad5/3-Δ24-hNIS replication effectively killed prostate cancer cells in vitro and in vivo. Also, the virus-mediated radioiodide uptake into prostate cancer cells in vitro and into tumors in vivo. Furthermore, Ad5/3-Δ24-hNIS with radioiodide was significantly more effective than virus alone in mice with prostate cancer xenografts. Conclusions: These results suggest that oncolytic adenovirus-mediated targeted radiotherapy might be a potentially useful option for enhancing the efficacy or adenoviral virotherapy. (Clin Cancer Res 2009;15(17):5396–403)

[1]  T. McDonnell,et al.  A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo , 2000, Oncogene.

[2]  A. Melcher,et al.  Radiation-Mediated Up-Regulation of Gene Expression from Replication-Defective Adenoviral Vectors: Implications for Sodium Iodide Symporter Gene Therapy , 2008, Clinical Cancer Research.

[3]  M. Ala-opas,et al.  Treatment of metastatic renal cancer with capsid-modified oncolytic adenoviruses , 2007, Molecular Cancer Therapeutics.

[4]  C. Balagué,et al.  Replicative adenoviruses for cancer therapy , 2000, Nature Biotechnology.

[5]  H. G. van der Poel,et al.  A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. , 2001, Cancer research.

[6]  Yang Zhang,et al.  [Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus]. , 2004, Ai zheng = Aizheng = Chinese journal of cancer.

[7]  Stephen L. Brown,et al.  Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[8]  U. Haberkorn,et al.  Gene therapy with sodium/iodide symporter in hepatocarcinoma , 2001, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[9]  E. Small,et al.  A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[10]  L. Johnson,et al.  An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy , 2000, Nature Medicine.

[11]  Jaetae Lee,et al.  Combination Therapy and Noninvasive Imaging with a Dual Therapeutic Vector Expressing MDR1 Short Hairpin RNA and a Sodium Iodide Symporter , 2008, Journal of Nuclear Medicine.

[12]  W. Vandertop,et al.  Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. , 2002, Cancer research.

[13]  B. Liu,et al.  Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[14]  K. Harrington,et al.  SPECT/CT imaging of oncolytic adenovirus propagation in tumours in vivo using the Na/I symporter as a reporter gene , 2007, Gene Therapy.

[15]  C. Ginter,et al.  The sodium/iodide Symporter (NIS): characterization, regulation, and medical significance. , 2003, Endocrine reviews.

[16]  D. Curiel,et al.  Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  N. Lemoine,et al.  Targeting sodium/iodide symporter gene expression for estrogen-regulated imaging and therapy in breast cancer , 2008, Cancer Gene Therapy.

[18]  Stephen L. Brown,et al.  Phase I study of noninvasive imaging of adenovirus-mediated gene expression in the human prostate. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[19]  S. Russell,et al.  Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Delta51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene. , 2007, Blood.

[20]  M. Tenhunen,et al.  Treatment of prostate cancer with Ad5/3Δ24hCG allows non-invasive detection of the magnitude and persistence of virus replication in vivo , 2007, Molecular Cancer Therapeutics.

[21]  D. Lee,et al.  In vivo long-term imaging and radioiodine therapy by sodium-iodide symporter gene expression using a lentiviral system containing ubiquitin C promoter , 2007, Cancer biology & therapy.

[22]  H. Moch,et al.  Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. , 2000, Human pathology.

[23]  D. Morton,et al.  Loss of heterozygosity of the retinoblastoma and adenomatous polyposis susceptibility gene loci and in chromosomes 10p, 10q and 16q in human prostate cancer. , 1994, British journal of urology.

[24]  S. Adelstein,et al.  Radiobiologic principles in radionuclide therapy. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  D. Nettelbeck,et al.  Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. , 2002, Cancer research.

[26]  U. Stenman,et al.  Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirus , 2005, Gene Therapy.

[27]  R. Kloos,et al.  Current Approaches to Primary Therapy for Papillary and Follicular Thyroid Cancer , 2001 .

[28]  H. Fang,et al.  Clinical trials with oncolytic adenovirus in China. , 2007, Current cancer drug targets.

[29]  L. Johnson,et al.  Gene delivery from the E3 region of replicating human adenovirus: evaluation of the 6.7 K/gp19 K region , 2001, Gene Therapy.

[30]  I. Tannock,et al.  A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer , 2000, Nature Medicine.

[31]  W. Vandertop,et al.  Differential Effects of Combined Ad5-Δ24RGD and Radiation Therapy in In vitro versus In vivo Models of Malignant Glioma , 2007, Clinical Cancer Research.

[32]  S. Russell,et al.  Dual Therapy of Ovarian Cancer Using Measles Viruses Expressing Carcinoembryonic Antigen and Sodium Iodide Symporter , 2006, Clinical Cancer Research.

[33]  J. Kang,et al.  Tumor-targeted radionuclide imaging and therapy based on human sodium iodide symporter gene driven by a modified telomerase reverse transcriptase promoter. , 2008, Human gene therapy.

[34]  C. Sherr.  Cancer Cell Cycles , 1996, Science.

[35]  J. Peabody,et al.  Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. , 2003, Cancer research.

[36]  D. Curiel,et al.  Evaluation of a selectively oncolytic adenovirus for local and systemic treatment of cervical cancer , 2004, International journal of cancer.

[37]  U. Stenman,et al.  Infectivity-Enhanced Adenoviruses Deliver Efficacy in Clinical Samples and Orthotopic Models of Disseminated Gastric Cancer , 2006, Clinical Cancer Research.

[38]  David Dingli,et al.  Genetically targeted radiotherapy for multiple myeloma. , 2003, Blood.

[39]  D. Dingli,et al.  Preclinical Pharmacology and Toxicology of Intravenous MV‐NIS, an Oncolytic Measles Virus Administered With or Without Cyclophosphamide , 2007, Clinical pharmacology and therapeutics.

[40]  R. Alemany,et al.  The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenoviruses. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[41]  M. Graham,et al.  Dual-expressing adenoviral vectors encoding the sodium iodide symporter for use in noninvasive radiological imaging of therapeutic gene transfer. , 2006, Nuclear medicine and biology.

[42]  T. DeWeese,et al.  CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. , 2001, Cancer research.

[43]  W. Lu,et al.  Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trial. , 2004, World journal of gastroenterology.

[44]  D. Tindall,et al.  In vivo sodium iodide symporter gene therapy of prostate cancer , 2001, Gene Therapy.

[45]  S. Jhiang,et al.  Expression, exon-intron organization, and chromosome mapping of the human sodium iodide symporter. , 1997, Endocrinology.

[46]  R. Desmond,et al.  Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic adenovirus , 2007, Gene Therapy.

[47]  P. Opolon,et al.  Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy. , 2000, Cancer research.

[48]  E. Dadachova,et al.  Kinetics of Perrhenate Uptake and Comparative Biodistribution of Perrhenate, Pertechnetate, and Iodide by Nai Symporter–expressing Tissues in Vivo , 2022 .

[49]  A. Hemminki,et al.  Systemic efficacy of oncolytic adenoviruses in imagable orthotopic models of hormone refractory metastatic breast cancer , 2007, International journal of cancer.